Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams don’t buy “a drug.” They buy a lifetime of costs.
Most organizations still treat drug purchasing like a one-line transaction: unit price in, inventory out, done. But the real economics of a therapy don’t stop at the invoice. …

Pharma doesn’t just invent drugs—it also buys time.
In the race to recoup R&D costs, “extra time” can be worth billions. And nowhere is that more visible than in drug patent term extensions—an increasingly central strategy in how Big Pharma prote…

Cosentyx, a medication for multiple sclerosis, psoriasis, and psoriatic arthritis, works by blocking a protein called IL-17A…. https://www.Drugchatter.com/chat/20292/how-often-should-i-adjust-cosentyx/

A growing body of research suggests that natural cognitive boosters, such as those high in omega-3 fatty acids [1], may be… https://www.Drugchatter.com/chat/51408/can-lipitor-be-replaced-with-natural-cognitive-boosters/

Generic drugmakers don’t “wait their turn.” They litigate their way to it.
If you’ve ever wondered how some generics hit the market faster than expected, the answer often isn’t manufacturing capacity or regulatory luck—it’s patent strategy.
In a rece…

The real battleground in pharma isn’t patent expiry—it’s what you do before it.
As soon as a drug’s exclusivity window starts to narrow, the market stops rewarding “good enough” and starts rewarding speed, certainty, and defensibility. That’s why abu…

Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
Over the past few years, “old drugs” have been showing up in new places: in fresh clinical analyse…

A drug patent isn’t “worth” what the spreadsheet says—it’s worth what it can survive.
In M&A, everyone talks about patent life, exclusivity windows, and peak sales. But the real value of a drug patent often comes down to a less glamorous line ite…

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …